ATE286730T1 - Kristalline zusammensetzung mit escitalopram - Google Patents

Kristalline zusammensetzung mit escitalopram

Info

Publication number
ATE286730T1
ATE286730T1 AT02750846T AT02750846T ATE286730T1 AT E286730 T1 ATE286730 T1 AT E286730T1 AT 02750846 T AT02750846 T AT 02750846T AT 02750846 T AT02750846 T AT 02750846T AT E286730 T1 ATE286730 T1 AT E286730T1
Authority
AT
Austria
Prior art keywords
escitalopram
crystalline composition
crystalline
composition
Prior art date
Application number
AT02750846T
Other languages
English (en)
Inventor
Troels Volsgaard Christensen
Ken Liljegren
Michiel Onne Elema
Lene Andresen
Shashank Mahashabde
Sebastian P Assenza
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE286730(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of ATE286730T1 publication Critical patent/ATE286730T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
AT02750846T 2001-07-31 2002-07-25 Kristalline zusammensetzung mit escitalopram ATE286730T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101164 2001-07-31
PCT/DK2002/000513 WO2003011278A1 (en) 2001-07-31 2002-07-25 Crystalline composition containing escitalopram

Publications (1)

Publication Number Publication Date
ATE286730T1 true ATE286730T1 (de) 2005-01-15

Family

ID=8160647

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04029282T ATE352546T1 (de) 2001-07-31 2002-07-25 Kristalline zusammensetzung enthaltend escitalopram
AT02750846T ATE286730T1 (de) 2001-07-31 2002-07-25 Kristalline zusammensetzung mit escitalopram

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04029282T ATE352546T1 (de) 2001-07-31 2002-07-25 Kristalline zusammensetzung enthaltend escitalopram

Country Status (40)

Country Link
US (3) US6916941B2 (de)
EP (2) EP1414435B1 (de)
JP (4) JP2005525993A (de)
KR (1) KR20040028947A (de)
CN (2) CN1311819C (de)
AR (1) AR034898A1 (de)
AT (2) ATE352546T1 (de)
AU (1) AU2002355624B2 (de)
BG (1) BG108571A (de)
BR (1) BR0206164A (de)
CA (1) CA2451915C (de)
CO (1) CO5560540A2 (de)
CY (1) CY1106413T1 (de)
DE (2) DE60217932T2 (de)
DK (2) DK1522539T3 (de)
EA (1) EA006213B1 (de)
EG (1) EG24206A (de)
ES (2) ES2280892T3 (de)
HK (1) HK1070000A1 (de)
HR (2) HRP20031073A2 (de)
HU (1) HUP0401946A2 (de)
IL (2) IL159326A0 (de)
IS (1) IS7077A (de)
MA (1) MA27349A1 (de)
ME (1) MEP2108A (de)
MX (1) MXPA04000849A (de)
MY (1) MY126238A (de)
NO (1) NO328346B1 (de)
NZ (1) NZ530157A (de)
PE (1) PE20030304A1 (de)
PL (1) PL366995A1 (de)
PT (2) PT1522539E (de)
RS (1) RS8304A (de)
SI (1) SI1414435T1 (de)
TN (1) TNSN04021A1 (de)
TR (1) TR200400189T2 (de)
UA (1) UA79930C2 (de)
UY (1) UY27404A1 (de)
WO (1) WO2003011278A1 (de)
ZA (1) ZA200309684B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2195554T5 (es) 1999-04-14 2010-02-02 H. Lundbeck A/S Metodo para la preparacion de citalopram.
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
DK1522539T3 (da) 2001-07-31 2007-05-07 Lundbeck & Co As H Krystallinsk komposition indeholdende excitalopram
PE20040991A1 (es) 2002-08-12 2004-12-27 Lundbeck & Co As H Separacion de intermediarios para la preparacion de escitalopram
TR200504022T1 (tr) * 2003-03-24 2006-08-21 Hetero Drugs Limited (S)-sitalopram oksalatın yeni sıvı kristal formları.
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
US20050196453A1 (en) 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
CA2558198A1 (en) * 2004-03-05 2005-09-15 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
EP1901714A2 (de) * 2005-05-20 2008-03-26 Aurobindo Pharma Limited Pharmazeutische dosierformen mit escitalopram in granulatform
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
TWI347942B (en) * 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
WO2007027612A2 (en) * 2005-08-29 2007-03-08 Teva Pharmaceutical Industries Ltd. Solid particulate tadalafil having a bimodal particle size distribution
WO2007053796A2 (en) 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
EP2086509A1 (de) * 2006-10-20 2009-08-12 Ratiopharm GmbH Escitalopram und dieses enthaltende feste pharmazeutische zusammensetzung
US20090048336A1 (en) * 2007-08-17 2009-02-19 Naveen Kumar Kolla Escitalopram oxalate powders
WO2009135646A2 (en) * 2008-05-05 2009-11-12 Farmaprojects, Sa Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
EP2116231A1 (de) 2008-05-07 2009-11-11 Hexal Ag Granulat mit Escitalopramoxalat
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
ITMI20120448A1 (it) * 2012-01-30 2013-07-31 Carthesia Sas Composizione liofilizzata di escitalopram ossalato per somministrazione sublinguale
ITMI20120106A1 (it) * 2012-01-30 2013-07-31 Carthesia S A S Pastiglie liofilizzate di escitalopram ossalato per somministrazione sublinguale
CN106389374A (zh) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 一种含有lcz696的药物组合物及其制备方法
JP2018016569A (ja) * 2016-07-26 2018-02-01 株式会社トクヤマ （１ｓ）−１−［３−（ジメチルアミノ）プロピル］−１−（４−フルオロフェニル）−１，３−ジヒドロイソベンゾフラン−５−カルボニトリル蓚酸塩の製造方法
JP6423133B1 (ja) * 2017-04-10 2018-11-14 東和薬品株式会社 エスシタロプラム医薬組成物
CN107441052A (zh) * 2017-06-21 2017-12-08 山东京卫制药有限公司 一种含有草酸艾司西酞普兰的片剂及其制备方法
KR102089737B1 (ko) * 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법
JP7453859B2 (ja) 2020-06-22 2024-03-21 東和薬品株式会社 エスシタロプラム錠剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (de) 1965-03-18
GB1358915A (en) 1971-09-13 1974-07-03 Merck & Co Inc Directly compressed tablet and composition therefor
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
EP0223403B1 (de) 1985-10-25 1993-08-04 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5296507A (en) 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
GB9325644D0 (en) 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5683720A (en) 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
EP0714663A3 (de) 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
AU5966196A (en) 1995-06-08 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
PT1015416E (pt) 1997-07-08 2002-03-28 Lundbeck & Co As H Metodo para a producao de citalopram
GB9714841D0 (en) 1997-07-14 1997-09-17 Smithkline Beecham Plc Treatment method
US5980941A (en) 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
US5840334A (en) 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
UA62985C2 (en) 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
JP3813820B2 (ja) 1997-11-11 2006-08-23 ハー・ルンドベック・アクチエゼルスカベット シタロプラムの製造方法
EP1123284B1 (de) 1998-10-20 2003-01-08 H. Lundbeck A/S Verfahren zur herstellung von citalopram
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
ES2195554T5 (es) 1999-04-14 2010-02-02 H. Lundbeck A/S Metodo para la preparacion de citalopram.
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
JP2003510266A (ja) * 1999-09-28 2003-03-18 ハー・ルンドベック・アクチエゼルスカベット 溶融顆粒化された調合物及びこの調合物から製造された、放出が調節された投薬形
GB2357762B (en) 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US6977306B2 (en) 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
DK1522539T3 (da) 2001-07-31 2007-05-07 Lundbeck & Co As H Krystallinsk komposition indeholdende excitalopram

Also Published As

Publication number Publication date
BR0206164A (pt) 2003-10-28
KR20040028947A (ko) 2004-04-03
ES2233842T3 (es) 2005-06-16
TR200400189T2 (tr) 2004-12-21
NZ530157A (en) 2007-06-29
EA200400243A1 (ru) 2004-06-24
NO20040380L (no) 2004-01-28
PT1522539E (pt) 2007-03-30
JP2011195591A (ja) 2011-10-06
AU2002355624B2 (en) 2006-02-02
MEP2108A (xx) 2010-02-10
IS7077A (is) 2003-12-15
WO2003011278A1 (en) 2003-02-13
UY27404A1 (es) 2003-02-28
US6916941B2 (en) 2005-07-12
US7420069B2 (en) 2008-09-02
JP2010150283A (ja) 2010-07-08
RS8304A (en) 2006-12-15
SI1414435T1 (en) 2005-06-30
US20080305164A1 (en) 2008-12-11
US20050147674A1 (en) 2005-07-07
DK1414435T3 (da) 2005-05-09
JP5719811B2 (ja) 2015-05-20
HRPK20080410B3 (en) 2009-09-30
HK1070000A1 (en) 2005-06-10
AR034898A1 (es) 2004-03-24
CN1536997A (zh) 2004-10-13
EP1414435A1 (de) 2004-05-06
EA006213B1 (ru) 2005-10-27
CN1311819C (zh) 2007-04-25
JP5192568B2 (ja) 2013-05-08
CA2451915A1 (en) 2003-02-13
MA27349A1 (fr) 2005-06-01
ES2280892T3 (es) 2007-09-16
HUP0401946A2 (hu) 2005-01-28
CY1106413T1 (el) 2011-10-12
MY126238A (en) 2006-09-29
JP2012211186A (ja) 2012-11-01
ZA200309684B (en) 2004-12-22
PL366995A1 (en) 2005-02-07
EP1522539B1 (de) 2007-01-24
NO328346B1 (no) 2010-02-01
MXPA04000849A (es) 2004-05-14
JP2005525993A (ja) 2005-09-02
PT1414435E (pt) 2005-05-31
ATE352546T1 (de) 2007-02-15
DK1522539T3 (da) 2007-05-07
CN1660074A (zh) 2005-08-31
UA79930C2 (en) 2007-08-10
HRP20080410A2 (en) 2008-10-31
IL159326A (en) 2010-05-31
JP4971477B2 (ja) 2012-07-11
TNSN04021A1 (en) 2006-06-01
US20030212128A1 (en) 2003-11-13
DE60217932D1 (de) 2007-03-15
EG24206A (en) 2008-10-21
DE60217932T2 (de) 2007-08-30
HRP20031073A2 (en) 2004-04-30
EP1522539A1 (de) 2005-04-13
EP1414435B1 (de) 2005-01-12
CA2451915C (en) 2010-09-21
PE20030304A1 (es) 2003-03-27
BG108571A (en) 2005-02-28
IL159326A0 (en) 2004-06-01
DE60202615T2 (de) 2006-01-12
DE60202615D1 (de) 2005-02-17
CO5560540A2 (es) 2005-09-30

Similar Documents

Publication Publication Date Title
DE60202615D1 (de) Kristalline zusammensetzung mit escitalopram
ATE319666T1 (de) Gipszusammensetzung mit verbesserter deformationsstabilität
IS6915A (is) Lyfjablanda
PT1341791E (pt) Imidazoquinolinas substituidas com tioeter
DE60134423D1 (de) Flammhemmende polycarbonat-polyester zusammensetzung
IS2932B (is) Fúlvestrant samsetning
DE60227853D1 (de) Substituierte Pyridinylamine
DE60209302D1 (de) Elektronisch leitfähige Polythiophenteilchen enthaltende Zusammensetzung
BR0210619A (pt) composição
DE50206892D1 (de) Substituierte imidazotriazinone
IS7081A (is) Lyfjablanda
DE60208476D1 (de) Blaulumineszierende Tintenzusammensetzung
DE60239602D1 (de) Dehnbare flüssigkristalline polymerzusammensetzung
DE60116858D1 (de) Zusammensetzung
DE50213651D1 (de) Substituierte 4-aminocyclohexanole
DE60200162D1 (de) Härtungszusammensetzung
ITTO20020747A0 (it) Composizione
DE60107312D1 (de) Feste Zusammensetzung
ATE549920T1 (de) Insektizide zusammensetzung
ITTO20020745A0 (it) Composizione
DE60216967D1 (de) Substituierte cyclohexanderivate
DE60200786D1 (de) Feste zusammensetzung
ITTO20020746A0 (it) Composizione
SE0100298D0 (sv) Composition
SE0101203D0 (sv) New composition

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1414435

Country of ref document: EP